Illumina Won’t Have to Pay Steep Fine After Court Holds European Commission Lacked Authority to Review Grail Merger
- September 06, 2024
The European Court of Justice has determined that the European Commission (EC) did not have jurisdiction to review genetic sequencing firm Illumina's $7 billion acquisition of cancer detection company Grail, according to a September 3 Illumina press release.
ARTICLE TAGS
You must be logged in to access this content.